MAP2K7 and metastatic melanoma: The response rate to BRAF and MEK inhibitors in metastatic melanoma patients with the BRAF V600 mutation is ca. 70% in selected patients, with less than 10% of patients having the highest response to progressive disease [55,56,57,58].